Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 13vPnC and 23vPS in Healthy Adults 60-64 Years
NCT00574548Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2007
- Primary completion
- Feb 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 13 in pneumococcal disease, sponsored by Pfizer. Started Nov 2007; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00574548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574548.